1. Home
  2. PRPO vs RNXT Comparison

PRPO vs RNXT Comparison

Compare PRPO & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Precipio Inc.

PRPO

Precipio Inc.

N/A

Current Price

$24.68

Market Cap

32.4M

Sector

Industrials

ML Signal

N/A

Logo RenovoRx Inc.

RNXT

RenovoRx Inc.

HOLD

Current Price

$0.94

Market Cap

36.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRPO
RNXT
Founded
N/A
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.4M
36.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PRPO
RNXT
Price
$24.68
$0.94
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$7.75
AVG Volume (30 Days)
14.5K
295.1K
Earning Date
11-14-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$22,800,000.00
$928,000.00
Revenue This Year
N/A
$2,795.35
Revenue Next Year
N/A
$272.69
P/E Ratio
N/A
N/A
Revenue Growth
30.95
N/A
52 Week Low
$3.90
$0.70
52 Week High
$28.50
$1.69

Technical Indicators

Market Signals
Indicator
PRPO
RNXT
Relative Strength Index (RSI) 56.69 51.11
Support Level $23.92 $0.92
Resistance Level $25.62 $0.93
Average True Range (ATR) 1.34 0.06
MACD -0.09 0.02
Stochastic Oscillator 67.00 76.75

Price Performance

Historical Comparison
PRPO
RNXT

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

About RNXT RenovoRx Inc.

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Share on Social Networks: